WILLIAMS AND JENSEN, PLLC for VERTEX PHARMACEUTICALS INCORPORATED
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, Lower Costs, More Cures Act of 2021 and H.R. 5376, "Inflation Reduction Act of 2022" (PL 117-169). Policies impacting U.S. address to the Covid-19 pandemic. General education about policies to improve health care outcomes for sickle cell disease.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & ofc VA 7; Sr Policy Adv, Majority Leader, Rep E Cantor; Sr Policy Adv, Republican Whip, Rep E Cantor; Sr Policy Adv, Majority Whip, Rep R Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox |
Medical/Disease Research/Clinical Labs MED
General education about FDA approval policies and NIH research activities. H.R. 7667, the Food and Drug Amendments of 2022. S.4348, the FDA Safety and Landmark Act. H.R.6833 Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180), including FDA User Fee Reauthorization Act of 2022.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & ofc VA 7; Sr Policy Adv, Majority Leader, Rep E Cantor; Sr Policy Adv, Republican Whip, Rep E Cantor; Sr Policy Adv, Majority Whip, Rep R Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox |
Medicare/Medicaid MMM
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, Lower Costs, More Cures Act of 2021 and H.R. 5376, "Inflation Reduction Act of 2022" (PL 117-169). Policies impacting U.S. address to the Covid-19 pandemic.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & ofc VA 7; Sr Policy Adv, Majority Leader, Rep E Cantor; Sr Policy Adv, Republican Whip, Rep E Cantor; Sr Policy Adv, Majority Whip, Rep R Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox |
Taxation/Internal Revenue Code TAX
Orphan drug tax credit issues and general business tax issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | Sch. C, Treasury; Associate Staff, House Rules Committee; LD, Rep. Scott McInnis |
| CHERYL LYNN JAEGER | Shd employee, Ofc of the Speaker 7 Ofc of VA 7; Sr. Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox |
Budget/Appropriations BUD
Policies impacting U.S. address to the Covid-19 pandemic. General education about policies to improve health care outcomes for sickle cell disease.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Republican Whip, Rep Cantor; Sr Policy Adv, Majority Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Cox |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.